Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 4Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Neoplasms 1Intestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ductal 1Carcinoma 1Breast Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Carboplatin 12Pemetrexed 11pembrolizumab 10Paclitaxel 6Cisplatin 6Erlotinib Hydrochloride 5Docetaxel 5Nivolumab 4Gefitinib 4spartalizumab 3osimertinib 3Gemcitabine 3EC145 3Crizotinib 3Afatinib 3technetium 99m etarfolatide 2pralsetinib 2fludarabine 2cemiplimab 2brigatinib 2alpha-2'-deoxythioguanosine 2aldesleukin 2Vinorelbine 2Radiotherapy 2Quality of Life 2MORAb-202 2Immunotherapy 2Drug Therapy 2Cyclophosphamide 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × canakinumab × Thoracic × Clear all
NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔